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1. Introduction
In animals, the detection of infectious agents requires speciﬁc
host pattern recognition receptors (PRRs) recognizing pathogen-
associated molecular patterns (PAMPs). The identiﬁcation and
characterization of the membrane-bound receptors TLRs (Toll-like
receptors) as PRRs have provided important insights in the
mechanisms of host defense [1]. Ten years ago, most PRRs
(including TLRs) were described as membrane receptors recogniz-
ing only extracellular PAMPs. By contrast, in plants, intracellular
disease resistance (R) proteins involved in the host defense against
speciﬁc pathogens have been already described [2].
Nod1 and Nod2 were identiﬁed in the early 2000s by Nu`n˜ez’s
team through homology to plant R proteins [3,4]. Indeed, both Nod
and plant R proteins are characterized by a N-terminal effector
domain, a centrally located nucleotide-binding domain (NBD) and
multiple leucine-rich repeats (LRRs) in their C-terminal end. TheN-
terminal effector domains of Nod1 and Nod2 comprise one or two
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A B S T R A C T
For almost 10 years, Nod2 has been known as a cytosolic innate receptor able to sense peptidoglycan
from Gram-positive and -negative bacteria and to trigger RIP2- and NF-kB-mediated pro-inﬂammatory
and antibacterial response. Mutations in the gene encoding Nod2 in humans have been associated with
Crohn’s disease (CD). Mechanisms by which Nod2 variants can lead to CD development are still under
investigation. The most admitted hypothesis suggests that the impaired function of Nod2 variants in
intestinal epithelial and phagocytic cells results in deﬁciencies in epithelial-barrier function which
subsequently lead to increased bacterial invasion and inﬂammation at intestinal sites. Very recent
results have just reinforced this hypothesis by demonstrating that Nod2 wild-type (unlike Nod2
variants) could mediate autophagy, allowing an efﬁcient bacterial clearance and adaptative immune
response. Other recent data have attributed new roles to Nod2. Indeed, Nod2 has been shown to activate
antiviral innate immune responses involving IRF3-dependent IFN-b production after viral ssRNA
recognition through a RIP2-independentmechanism requiring themitochondrial adaptor proteinMAVS.
Recently, Nod2 has been also shown to be exquisitely tuned to detect mycobacterial infections and
mount a protective immunity against these pathogens.
 2010 Published by Elsevier Inc.
* Corresponding author. Tel.: +32 4 3662434; fax: +32 4 3664534.
E-mail address: S.Legrand@ulg.ac.be (S. Legrand-Poels).
G Model
BCP 10649 1–11
Please cite this article in press as: Lecat A, et al. The protein Nod2: An innate receptor more complex than previously assumed. Biochem
Pharmacol (2010), doi:10.1016/j.bcp.2010.07.016
Contents lists available at ScienceDirect
Biochemical Pharmacology
journal homepage: www.e lsev ier .com/ locate /b iochempharm
0006-2952/$ – see front matter  2010 Published by Elsevier Inc.
doi:10.1016/j.bcp.2010.07.016
caspase recruitment domains (CARD), respectively [3,4] (Fig. 1).
While Nod1 is ubiquitous, Nod2 seems to be more restricted to
myelomonocytic cells (monocytes/macrophages, granulocytes),
dendritic cells and intestinal epithelial cells [4–6]. More impor-
tantly, Nod2 expression can be upregulated by pro-inﬂammatory
stimuli in myelomonocytic and epithelial cells [5].
Very rapidly after their identiﬁcation, Nod1 and Nod2 were
shown to induce NF-kB activation after recognition of bacterial
components through their LRRs and were suspected to play a role
in innate immunity [7]. It was the ﬁrst evidence showing the
recognition of pathogen-associated compounds by cytosolic
receptors in mammal cells. More interestingly, three variants
within or near the LRRs domain of Nod2 were simultaneously
identiﬁed and genetically associated with susceptibility to Crohn’s
disease (CD) [8,9] (Fig. 1).
Altogether, these data elicited many researches on the Nod2
protein concerning the Nod2-mediated transduction pathways,
the precise bacterial structure recognized by Nod2, the mechan-
isms by which the Nod2 variants favor the CD and the physiologic
roles of Nod2 in innate and adaptative immune response. The
identiﬁcation of Nod1 and Nod2 also stimulated homology
searches revealing a growing family of structurally related proteins
with centrally located NBD and carboxy-terminal LRRs. This family
currently called NLR (Nod-like receptor) includes 23 members in
humans and is divided in ﬁve subfamilies according to their
effector domain [10]. Next to Nod1 and Nod2 known to induce the
NF-kB signalling pathway, others NLRmembers such as NLRP1 and
3 (previously called NALP1 and 3) result in the activation of the
inﬂammasome in response to speciﬁc PAMPs and DAMPs (danger-
associated molecular patterns) [10]. It is now well admitted that
the cytosolic NLR family contributes to the immune response
against pathogens in collaboration with the membrane-bound
TLRs and another recently identiﬁed family of cytosolic receptors
called RLR (RIG-I-like receptor) [11].
This review is dedicated to the Nod2 protein and focuses on
recent data attributing new potential roles to Nod2.
2. Nod2-mediated signal transduction pathways
2.1. Nod2-dependent NF-kB and MAPKs activation pathways in
response to bacterial infection
The Nod-mediated NF-kB activation pathway has been
extensively studied. Nod1 was initially identiﬁed by homology
with Apaf-1, an inducer of apoptosis [3]. In addition of interacting
with caspases, Nod1 was shown to interact with RICK (RIP-like
interacting CLARP kinase), currently called RIP2 (receptor-inter-
acting protein 2), a CARD-containing serine-threonine kinase and
by this way to promote NF-kB activation [3]. The structural and
functional similarity between Nod1 and Apaf-1 as well as those of
RIP2 and RIP1, a serine-threonine kinase recruited to the TNFa
receptor 1 (TNFR1) suggested a ‘‘induced proximity’’ model for
RIP2 and RIP1-mediated NF-kB activation which is similar to the
mechanism for activation of caspases during apoptosis [12].
According to this model, after Nod1 overexpression or TNFa
binding, both Nod1 or TNFR1 could oligomerize and bind RIP2 or
RIP1 by CARD homophilic or DD (death domain) interactions,
respectively. RIP2 and RIP1 also bind to NEMO (NF-kB essential
modiﬁer) or IKKg, the regulatory subunit of the IKK complex (IkBa
kinase complex). The RIP2 or RIP1 recruitment to Nod1 or TNFR1
complexes, respectively, could allow the proximity of IKK
complexes leading to NF-kB activation. Shortly after, Nod2 was
identiﬁed and was shown to induce NF-kB activation by a similar
RIP2-mediated mechanism [4]. In support of the ‘‘induced
proximity’’ model, the kinase activity of RIP2 is not necessary
for Nod1 and Nod2-mediated NF-kB activation but RIP2 seems to
play simply the role of scaffold protein [12]. However, recent data
highlighted the central role of the RIP2 kinase activity in conferring
stability to the protein and accordingly in the preservation of Nod1
and Nod2-mediated innate immune responses [13].
Considering the structural homology between Nod1/Nod2 and
plant R proteins, experiments were performed to determine
whether Nod1/Nod2 might regulate the cellular response to
microbial components. First, Nod1 and Nod2were shown to confer
responsiveness in terms of NF-kB activation to bacterial compo-
nents through their LRRs [7]. However, when various bacterial
sources were used, the Nod2 response pattern was shown to be
different from that observed with Nod1. Indeed, after elucidation
of the precise bacterial structure recognized by Nod1 and Nod2, it
was clear that Nod1 and Nod2 were not devoted to sense the same
pathogens. While the minimal motif detected by Nod1 is the
peptidoglycan (PGN) fragment g-D-glutamyl-meso-diaminopime-
lic acid (iE-DAP), Nod2 recognizes the PGN fragment MurNAc-L-
Ala-D-isoGln called MDP for muramyl dipeptide [14,15]. The iE-
DAP is commonly present in Gram-negative bacteria whereasMDP
is found in both Gram-negative andGram-positive bacteria (Fig. 2).
The mechanism by which Nod1 and Nod2 sense iE-DAP or MDP,
respectively, is currently unknown. It probably involves not yet
identiﬁed partners.
The identiﬁcation of MDP or iE-DAP as Nod-activating PAMPs
elicited questions. For example, how a subunit of PGN can reach a
cytosolic receptor? Several mechanisms were proposed according
to the cell type and the bacterial agent. Fig. 3 summarizes what is
known about the modes of MDP intracellular delivery. The ﬁrst
mechanism concerns invasive bacteria which, after their internali-
zation in non-phagocytic cells, can escape from the vacuole into
the cytosol where they replicate. [16]. PGN must be continuously
remodeled during bacterial growth. In some Gram-negative
bacteria, PGN breakdown mediated by transglycosylases and
peptidases releases fragments in the periplasm which are re-
imported into the cytoplasm for recycling [17]. A minor fraction of
these PGN fragments can be exported in the cytosol of infected
mammal cells (Fig. 3A). Indeed, it was shown that muramylpep-
tides shed by Shigella in epithelial cells are able to trigger Nod1-
mediated NF-kB activation [18]. Muramylpeptides can be also
generated in the cytosol after invasion by Gram-positive bacteria.
Indeed, the Nod2 ligand, muramyl dipeptide (MDP) can potentially
be generated in Listeria monocytogenes-infected cells upon PGN
cleavage by secreted autolysins p60 and NamA [19] (Fig. 3A).
Bacterial components can be also delivered into the cysosol
through bacterial secretion systems or pore-forming toxins. While
this mode of intracellular delivery allows PAMPs detection by
some members of the NLR family, such a report was not yet
described for Nod2. A third mechanism allowing PAMPs release
inside cytosol involves phagocytosis by macrophages. Nod2 was
shown to be activated in stimulated macrophages by bacterial
ligands generated in the phagosome and transported to the cytosol
[20] (Fig. 3B). Finally, extracellular MDP can get access to the host





















































































































Fig. 1. Most common Nod2 mutants associated to Crohn’s disease. Nod2 has a
tripartite structure with two N-terminal CARD domains, a central NBD domain and
C-terminal LRRs. The three most common polymorphisms associated with Crohn’s
disease are shown: two missense mutations R702W and G908R and a frameshift
mutation L1007fsinsC.
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hPepT1 [21] or by a clathrin-and dynamin-dependent endocytic
pathway [22,23] (Fig. 3C).
The subcellular distribution of Nod2 was also further investi-
gated. Besides its cytosolic location, Nod2 is associated with the
plasma membrane in epithelial and monocytic cells [24–29].
Interestingly, Nod2 localizes to the basolateral membrane in
polarized intestinal epithelial cells [25]. Nod2 as well as Nod1 are
also recruited in membrane rufﬂes through Rac1 interaction and
the NF-kB activation pathways mediated by Nod2 and Nod1 are
modulated by actin cytoskeleton [27,29,30]. In MDP-treated
monocytic cells, Nod2 is translocated to the membrane by a













Fig. 3. Modes of MDP intracellular delivery. (A) MDP intracellular delivery by invasive bacteria. Muramylpeptides are shed by Gram-negative bacteria or released after L.
monocytogenes PGN cleavage by secreted autolysins. (B) MDP intracellular release during phagocytosis. (C) Extracellular MDP transport into the cell through the intestinal
transporter hPepT1 or endocytosis.
Fig. 2. Nod1 and Nod2 agonists. A schematic representation of Gram-negative bacteria cell wall is shown with the periplasmic space comprised between outer and inner
membranes. Peptidoglycan located in the periplasm is composed of linear chains containing two alternating amino sugars, N-acetyl glucosamine (NAG) and N-acetyl
muramic acid (NAM) attached by short peptides. Theminimalmotif recognized byNod1 is the fragmentg-D-glutamyl-meso-diaminopimelic acid (iEDAP)while Nod2 detects
the PGN fragment MurNAc-L-Ala-D-isoGln called MDP for muramyl dipeptide.
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Nod1 are recruited to invasion foci of Shigella ﬂexneri in HeLa cells,
probably also by a mechanism dependent on actin cytoskeleton
[26,30]. The recruitment of Nod2 in Rac1-induced dynamic
cytoskeletal structures could be a strategy to rapidly mobilize
Nod2 duringMDP endocytosis or bacterial invasion and to ensure a
close proximity between Nod2 and its ligand. Furthermore, Nod2
promotes themembrane recruitment of RIP2, the serine–threonine
kinase involved in NF-kB activation downstreamof Nod2 [28]. This
membrane compartmentalization mechanism seems to be re-
quired for an optimal activity of the Nod2-RIP2 complexes and has
been already described for integral membrane TLRs and TNFRI to
regulate downstream signalling [31,32]. Among the three most
common mutants associated with CD, the Nod21007FS mutant,
deleted from its 33 carboxy-terminal amino acid residues, is the
only one to be unresponsive to MDP and to be delocalized in the
cytoplasm [24,28]. However, the targeting of the Nod21007FS
mutant to the plasma membrane did not restore the ability to
activate NF-kB in response to MDP meaning that this variant has
another defect making it unable to recognize MDP [28].
Since 2003, several non-degradative ubiquitination events have
been shown to play a key role in various NF-kB activation
pathways [33]. TheMDP-induced Nod2 signalling also appeared to
involve ubiquitination steps. Indeed, Nod2 was shown to induce
RIP2-dependent K63-linked ubiquitination of NEMO at K285, and
NEMO ubiquitination was impaired by Nod2 mutations associated
with Crohn’s disease [34]. Subsequent studies revealed that Nod2-
mediated NF-kB activation requires K63-linked ubiquitination of
RIP2; the key ubiquitination acceptor site was mapped to K209
[35]. Both polyubiquitination events promote the recruitment of
the TAK1 kinase, which activates IKK complex [35–38]. Very
recently, cIAP1 and cIAP2 (cellular inhibitor of apoptosis proteins 1
or 2) were identiﬁed as E3 ubiquitin ligases required for RIP2
ubiquitination and Nod2-mediated NF-kB activation [39].
The current model of Nod2-mediated NF-kB activation is
illustrated in Fig. 4. In resting cells, Nod2 stays in an autoinhibited
conformation through intramolecular inhibition of the NBD domain
by LRRs [4]. Upon MDP recognition through LRRs, conformational
modiﬁcations allow nucleotide triphosphate binding and Nod2
oligomerization through the NBD. MDP or bacterial invasion also
promote Nod2 recruitment to the plasma membrane or invasion
foci, respectively, by a cytoskeleton-dependent mechanism [26,29].
Nod2 oligomerization induces the RIP2 recruitment through
homotypic CARD-CARD interactions. RIP2 interacts with IKKg
through its intermediate region. The induced proximity of RIP2
molecules promotes the K63-linked polyubiquitination of NEMO as
wellas itsownK63-linkedpolyubiquitinationachievedbycIAP1and
cIAP2 at lysine 209 located in its kinase domain. Both ubiquitination
events are crucial for the TAK1 complex recruitment allowing the
subsequent IKK complex activation through the phosphorylation of
the IKKb subunit. This is followed by the phosphorylation and
degradation of IkBa, releasing NF-kBwhich can then translocate to
the nucleus and transactivate targets genes. Interestingly, Nod2-
mediatedNF-kB activation proceeds by amechanismvery similar to
the one used by TNFR1 [33]. Indeed, after activation by their
respective ligandandoligomerization, TNFR1orNod2recruitRIP1or
RIP2 to the plasma membrane, respectively. Both scaffold proteins
RIP1 or RIP2 interact with NEMO and become K63-linked
polyubiquitinated by cIAP1 and cIAP2. These events are followed
by TAK1 complex recruitment and IKK complex activation.
MDP recognition by Nod2 also leads to the activation of MAPKs
(mitogen-activated protein kinases), including p38, ERK (extracel-
lular signal-regulated protein kinase) and JNK (c-Jun N-terminal
kinase) [37]. Although the scaffold protein RIP2 and the kinase
TAK1 are also involved in the Nod2-mediated MAPKs activation
(Fig. 4), the downstream effectors are less well characterized. Little
is known about the molecular mechanisms by which Nod2
functionally coordinates separate signalling pathways. Some
signalling intermediates have been shown to differentially
modulate the Nod2-mediated NF-kB and MAPKs activation. It is
the case of the adaptor protein CARD9 which associates with Nod2
in response to MDP and has a critical function in Nod2-dependent









































































Fig. 4. Nod2-mediated NF-kB and MAPKs activation pathway in response to bacterial infection. In resting cells, Nod2 stays in an autoinhibited conformation through
intramolecular inhibition of the NBD domain by LRRs. Upon MDP recognition through LRRs, conformational modiﬁcations allow nucleotide triphosphate binding and Nod2
oligomerization through the NBD followed by RIP2 recruitment through homotypic CARD-CARD interactions. RIP2 also interacts with IKKg through its intermediate region.
The induced proximity of RIP2 molecules promotes the K63-linked polyubiquitination of IKKg as well as its own K63-linked polyubiquitination achieved by cIAP1 and cIAP2
at lysine 209 located in its kinase domain. Both ubiquitination events are crucial for the TAK1 complex recruitment allowing the subsequent IKK complex activation through
the phosphorylation of the IKKb subunit. This is followed by the phosphorylation and degradation of IkBa, releasing NF-kB which can then translocate to the nucleus and
transactivate target genes. RIP2 and TAK1 recruitment also induce MAPKs activation. CARD 9 plays a critical role in Nod2-mediated p38 and JNK activation.
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pathway [40].MEKK4, aMAP3Kwhich binds to RIP2, is required for
Nod2-induced p38 and ERK activation while it downregulates
Nod2-dependent NF-kB pathway [41]. Another report has shown
that the K63-linked polyubiquitination of RIP2 on another residue
as K209 by the E3 ubiquitin ligase ITCH primes the Nod2-mediated
MAPKs pathway at the expense to the NF-kB one [42].
Both NF-kB and MAPKs pathways contribute to the Nod2-
mediated inﬂammatory and immune response. In vitro studies
have shown that activation of human epithelial cells by MDP
induces the production of pro-inﬂammatory cytokines (TNFa, IL-
6), chemokines (IL-8, MIP2, MCP-1,. . .) and antimicrobial peptides
[43]. In antigen-presenting cells, activation of Nod2 also leads to
the secretion of pro-inﬂammatory cytokines such as IL-6, TNFa, IL-
1b, IL-10, IL-18, IL-12 and chemokines IL-8 and RANTES [43,44].
Several proteins exerting modulating functions on Nod2-
mediated NF-kB activation were identiﬁed in the search for
binding partners of Nod2. The cell polarity protein Erbin, the
GTPase-activating protein Centaurin-b1 (CENTB1) and the angio-
associated migratory cell protein (AAMP) bind to Nod2 and
negatively regulate Nod2-dependent NF-kB activation while the
GRIM-19 protein that also associates with Nod2 appears to
positively modulate Nod2 signalling [25,26,45–47]. Since Erbin
and CENTB1 expression is upregulated after Nod2 activation, both
proteins could mediate a negative feedback.
2.2. Nod2-mediated IRF3 activation in response to viral infection
Very recent results have expanded the function of Nod2 beyond
detection of peptidoglycan [48]. Indeed, Sabbah et al. found that
Nod2 (and not Nod1) could confer responsiveness to ssRNA in terms
of IRF3 activation and IFN-b production. Furthermore, wild-type
cells expressingNod2-speciﬁc small interfering RNAor BMMs (bone
marrow-derived macrophages) from Nod2-deﬁcient mice failed to
induce an antiviral response after ssRNA transfection. A signiﬁcant
Nod2-mediated IRF3 activation was also observed after infection
with RSV (respiratory syncytial virus), VSV (vesicular stomatitis
virus) or inﬂuenza virus, each of them has a ssRNA genome.
Like with MDP, the ssRNA recognition mechanism is still
unknown. The authors demonstrated the recovery of VSV-speciﬁc
RNA in Nod2-containing complexes after VSV infectionwhich does
not likely result from a direct binding between Nod2 and ssRNA
but rather involves bridging proteins.
To further investigate the molecular mechanism involved in
Nod2-dependent IRF3 activation, authors turned to MAVS, the
mitochondrial antiviral signalling protein which mediates RLRs
(RIG-I and MDA-5)-induced antiviral response [49]. They showed
thatMAVS extinction impaired Nod2-dependent IFN-b production
after RSV infection. Interestingly, after RSV infection, Nod2
translocated to the mitochondria where it associated with MAVS
(Fig. 5). Unlike RIG-I, the CARDs of Nod2 were not important for its
interaction with MAVS. However, the NBD and LRR domains were
required for the MAVS association and Nod2-dependent IRF3
activation. Interestingly, another NLR family member, NLRX1, was
shown to interact with MAVS through its NBD and LRR domains
leading to a downregulation of RIG-I- and MDA5-mediated
antiviral response [50].
Since the expression of interferon genes also requires NF-kB
activation in addition to IRF3, Sabbah et al. conﬁrmed it was also
the case for Nod2-mediated IFN-b production. On the basis of
these results, they speculated that the mechanism by which Nod2
induces IFN-b production in response to ssRNA is similar to that of
RLRs and involves the mitochondrial adaptor MAVS which, in turn,
recruits downstream signalling complexes for NF-kB and IRF3
activation [49].
Altogether, these data demonstrate that Nod2 can trigger at
least two distinct pathways from two different cellular locations
(Fig. 5): the MDP-induced pro-inﬂammatory and antibacterial
pathway initiated from the plasmamembrane after recruitment of
RIP2 and downstream signalling complexes leading to NF-kB and
MAPKs activation and the ssRNA-induced antiviral pathway
originating from the mitochondria after Nod2 association with
MAVS and recruitment of the downstream signalling complexes
required for NF-kB and IRF3 activation. Interestingly, transfection
of Nod2 alone can induce the RIP2-dependent pathway without
any external stimuli [4] but cannot trigger IRF3 activation in the
absence of viral ssRNA [48]. This observation suggests that Nod2
involvement in each pathway is fundamentally different. All these
new data are also very well summarized and illustrated in a recent
review on NonInﬂammasome NLRs [51].
2.3. Nod2-mediated autophagy in response to bacterial infection
Autophagy is a highly conserved degradation process in which
portions of cytoplasm or damaged organelles become surrounded
by a double-membrane delineating a vacuole called autophago-
some which is eventually targeted for fusion with lysosomes [52].
This mechanism usually cytoprotective is induced in response to
many stress conditions [53]. In particular, autophagy has emerged
as a critical pathway of host defense against viral, bacterial and
parasitic infections [54]. A link between intracellular bacteria-
sensing receptors and the induction of autophagy has already been
established in plants and insects [55,56]. Such a link between the
NLR receptors, Nod1 and Nod2, and autophagy has just been
demonstrated in mammals [57,58].
Travassos et al. showed that the intracellular delivery of iEDAP
or MDP induces autophagy by amechanism dependent on Nod1 or
Nod2, respectively [57]. Accordingly, the autophagy triggered by
invasive bacteria known to be sensed by Nod1 or Nod2 was shown
to require Nod1 or Nod2, respectively, and contribute to Nod1 or
Nod2-mediated host defense [57,58]. Both Nod1 and Nod2-
induced autophagy by a mechanism independent on NF-kB but
involving the key autophagy regulator ATG16L1 [57] (Fig. 6). Both




































































































Fig. 5. Two distinct Nod2-mediated pathways:MDP-induced pro-inﬂammatory and
antibacterial pathway initiated from the plasma membrane and ssRNA-induced
antiviral pathway originating from the mitochondria. MDP recognition by Nod2
leads to NF-kB and MAPKS activation through a RIP2-mediated mechanism while
ssRNA sensing by Nod2 induces IRF3 activation through MAVS.
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plasma membrane. During bacterial invasion, ATG16L1 was
recruited to bacterial entry sites with Nod1 or Nod2. Their ﬁndings
suggest that Nod proteins serve as a molecular scaffold for the
autophagy machinery and by this way act as nucleation sites for
autophagy initiation [57]. RIP2 involvement in Nod2-dependent
autophagy is a matter of debate. Indeed, Travassos et al. showed
Nod2-dependent autophagy was not impaired in RIP2-deﬁcient
MEFs, while Cooney et al. demonstrated a role of RIP2 in Nod2-
mediated autophagy in human dendritic cells (DCs) through RIP2-
speciﬁc siRNA transfection or RIP2 inhibitor treatment [57,58]. It
will be crucial to deﬁne the exact molecular complex by which
Nod2 acts to induce autophagy.
As previously reported, the most common CD mutant, Nod2fs,
failed to localize to the plasma membrane [24]. Interestingly,
Travassos et al. also showed that Nod2fs sequesters ATG16L1 in the
cytosol and thereby prevents it from translocating to bacterial
invasion foci and initiating autophagy (Fig. 6) [57].
3. Nod2 involvement in other signalling pathways
3.1. Antiviral pathway involving OAS2-RNase-L
The expression of oligoadenylate synthetases (OAS) is induced
in response to type I interferons [59]. These enzymes are activated
by viral dsRNA binding. OAS-dsRNA complexes are then able to
convert ATP into 20,50-linked oligomers of adenosine (2-5A)
which, in turn, can bind to RNase-L, thereby enabling RNase-L to
cleave viral and cellular RNAs. Both degradation events impair
further viral production. On the other hand, by cleaving some self
mRNAs, RNase-L produces small RNAs which act as a ligand for
intracellular receptors such as RIG-I and MDA-5. These receptors
mediate a positive feedback phenomenon by inducing type I IFNs
production.
Nod2 was shown to interact with OAS2 and enhance RNAse-L
activity in cells treated with poly(I:C), a mimic of double-stranded
RNA virus infection [60]. These results suggest that Nod2 would be
not only able tomediate IFN-b production after infection by ssRNA
virus but could be also involved through an indirect mechanism in
RLRs-dependent type1 interferons expression after dsRNA virus
infection. This last point needs to be further explored.
3.2. Antibacterial pathway involving DUOX2-induced ROS production
Given the link between plant R proteins and pathogen-induced
reactive oxygen species (ROS) production [61] as well as the
interaction between NOX family members and components of the
TLR signalling cascade [62], Lipinski et al. explored whether Nod2
signalling mediated ROS production and if this mechanism
contributed to host defense [63]. They showed a rapid and
signiﬁcant Nod2-dependent ROS production in MDP-stimulated
intestinal epithelial cells (IECs) which was mainly mediated by
DUOX2, a dual oxidase generating hydrogen peroxide. Interesting-
ly, DUOX2 expression was upregulated by inﬂammatory stimuli
and was increased in IECs originating from inﬂamed tissue in
comparison to non-inﬂamed tissue. Nod2 was shown to interact
with DUOX2 through its LRRs. Nod2 mediated a DUOX2-
dependent protection against bacterial cytoinvasion which could
be attributed to a direct effect involving the generation of
bactericidal ROS and an indirect mechanism consisting of NF-kB
signalling upregulation by ROS. Interestingly, the Nod2L1007f-
sinsC mutant did not lead to a signiﬁcant ROS production and gave
only reduced protection against bacterial cytoinvasion.
4. Role OF Nod2 in innate immune response
The identiﬁcation of the Nod proteins sensing the same
pathogens and triggering the same transduction pathways as
TLRs elicited the question of redundancy between these PRRs.
Several studies in vitro demonstrated that Nod2 andNod1 agonists
have a synergistic effect on TLRs-mediated inﬂammatory cytokines
production, which could potentiate the cellular response against
pathogens [64–66]. A role of Nod2 as a negative regulator of TLR2-
mediated IL-12 secretion has also been suggested but does not
seem to be a universal phenomenon [67,68]. On the other hand, an
essential role of Nod2 in host defense against some pathogens has
been demonstrated in some in vivo models.
Nod2/ mice challenged via intragastric dosing with L.
monocytogenes, a Gram-positive enteroinvasive bacteria, were
more susceptible to infection than wild-type mice [68]. However,
Nod2/ mice challenged with L. monocytogenes by intravenous or
intraperitoneal injection did not show any signiﬁcant difference
neither in bacteria recovering nor in survival. These data
emphazize the critical role of Nod2 in innate immunity in the
intestinal tract. Nod2 could play this role at least partially by
mediating the expression of intestinal antimicrobial peptides
known as cryptdins in mice and a-defensins in humans [68].
Furthermore, in mice made insensitive to TLRs by previous
exposure to microbial ligands and then submitted to systemic
infection with L. monocytogenes, Nod1 and Nod2 were required for
the bacterial clearance and mice survival [69]. Altogether, these
data suggest that Nod2 plays a critical role in host defense when
TLRs signalling is reduced like in intestinal cells or inhibited via
tolerization. Such a tolerization phenomenon can originate from
the continuous exposition to commensal bacteria like it is the case
for intestinal cells.
Several studies also focused on the potential involvement of
Nod2 in protective immunity to other intracellular pathogens such
as mycobacteria. In general, the secretion of pro-inﬂammatory
cytokines by monocytes/macrophages in response to infection by
Gram-positive or Gram-negative intracellular bacteria is not
signiﬁcantly affected by Nod2 deﬁciency because TLRs often well-
expressed in this kind of cells fulﬁll this function. By contrast, Nod2
was required for optimal inﬂammatory response in macrophages
and dendritic cells after infection with live Mycobacterium
tuberculosis, suggesting Nod2 and TLRs are non-redundant recogni-
tion systems of M. tuberculosis [70–72]. Furthermore, in M.





































































































Fig. 6. Nod2-mediated autophagy in response to bacterial invasion. Nod2 can serve
as a molecular scaffold for the autophagy machinery. The most common variant
Nod2L1007fsinsC associated to Crohn’s disease, by sequestering ATG16L1, fails to
induce autophagy.
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led to higher pulmonary bacterial burden and decreased host
resistance to chronicmycobacterial infection [73]. The sameauthors
further investigated the mechanism by which Nod2 mediates a so
important contribution in innate immune response against M.
tuberculosis in comparison with other intracellular bacteria. An
interesting obervation is that mycobacteria convert their MDP into
anN-glycolylated form through the action of N-acetylmuramic acid
hydroxylase (NamH) while MDP is N-acetylated in most bacteria
[74]. They showed thatN-glycolylMDP ismorepotent thanN-acetyl
MDP in activating Nod2-mediated signalling in vitro [75]. In mice
challenged intraperitoneally with live wild-type Mycobacterium
smegmatis or namH-deﬁcient M. smegmatis, Nod2-dependent
immune responses were disrupted in the absence of NamH [75].
Altogether, thesedata suggest thatNod2maybeexquisitely tunedto
detect mycobacterial infections.
Very recently, Nod2 was also shown to be a critical component
of host antiviral defense mechanisms. Indeed, after having shown
that viral ssRNA or RSV infection induced Nod2-mediated IFNb
production in vitro, Sabbah et al. infected wild-type or Nod2-
deﬁcient mice with a sublethal dose of RSV by intranasal
inoculation [48]. They observed an increase of Nod2 expression
in RSV-infected lungs which correlated with the interferon-
induction kinetics, suggesting an important role for Nod2 in
interferon production. Indeed, Nod2-deﬁcient mice had lower IFN-
b production in the respiratory tract and higher viral titers than
wild-type mice. Nod2/ mice also showed more severe lung
pathology, lost considerably more body weight and had dimin-
ished survival relative to their wild-type counterpart.
5. Role of Nod2 in adaptative immune response
The innate immune system not only represents the ﬁrst line of
defense against invading pathogens but it is also responsible for
instructing appropriate adaptative immune responses. While the
key role of Nod2 protein in innate immune defense has been
established, until recently few studies have examined its contribu-
tion to the adaptative immune response. However,MDPhad already
been identiﬁed as the minimum effective component of CFA
(complete Freund’s adjuvant) in 1974 [76]. It is only in 2005,
following the identiﬁcationofMDPasaNod2agonist [14,15], that its
adjuvanticity couldbeattributed toNod2, sinceNod2-deﬁcientmice
could not mount a normal humoral response after immunization
withMDPplus an antigen [68]. Since then, themechanismbywhich
MDPexerts its adjuvant activity throughNod2was further explored.
MDP-induced Nod2 signalling in human dendritic cells (DCs)
was shown to promote the differentiation of humanmemory CD4+
T cells into T-helper 17 (Th17) cells [77]. In a mouse model, MDP-
stimulated Nod2 triggered a potent Ag-speciﬁc immune response
with a Th2-type polarization proﬁle [78]. In this samemodel, Nod2
was also critical for the induction of both Th1- and Th2-type
responses following costimulation with TLR agonists. Dendritic
cellswere shown to play a central role in this synergistic priming of
adaptative immunity.
TLRs are known to inﬂuence the adaptative immune response
not only by inducing the expression of costimulatory molecules
but also by priming the antigen presentation pathway in dendritic
cells, both events being required for naı¨ve T cells activation [79].
Since Nod2 has been recently shown to mediate autophagy [58]
and given that autophagy has a major role in antigen presentation,
with constitutive fusion of autophagosomes with multivesicular
MHC class II-loading compartments in antigen-presenting cells
[80], the potential link between Nod2 and MHC class II antigen
presentation machinery was investigated. MDP treatment of
primary immature human DCs induced Nod2-dependent autop-
hagy, which, in turn, led to an increase of MHC class II (but not of
MHC class I) surface levels [58]. To further determine the effect of
Nod2-mediated autophagy on antigen presentation, Cooney et al.
infected DCswith Salmonella enterica or recombinant S. enterica Cfr
expressing the C-fragment of tetanus toxin before exposure to
autologous CD4+ T cells of tetanus-immune individuals. The
antigen-speciﬁc proliferation of autologous CD4+ T cells was
signiﬁcantly reduced after knockdown of Nod2 or ATG16L1, a key
autophagy mediator, suggesting that Nod2-dependent autophagy
can contribute to MHC class II antigen presentation (Fig. 7A).
Consistent with previous data showing that the CDmutant Nod2fs
failed to induce autophagy, Nod2fs-expressing DCs, after infection
with S. enterica Cfr, were much less efﬁcient to stimulate tetanus
toxin-speciﬁc CD4+ T cells proliferative responses.
In another very recent work, Nod signalling was shown to
enhance DCs-mediated cross-priming [81]. DCs have the unique
ability to deliver exogenous Ag to the MHC class I-restricted Ag
presentation pathway and generate CD8+ T cell immunity to viral
infection and cancer, a phenomenon known as cross-priming [82].
In this study, authors demonstrated that injecting ligands for Nod2
(and Nod1) along with Ag (OVA) into wild-type mice signiﬁcantly
enhanced the cross-priming of OVA-speciﬁc CD8+ T cells by CD8a+
DCs. Cross-presentation can proceed according to several mechan-
isms [82]. OVA cross-presentation is mediated by the early
endosomes pathway. In this model, soluble antigens taken up
by the mannose receptor (MR) and targeted to a stable early
endosomal compartment are translocated into the cytosol where
they are degraded into antigenic peptides by the proteasome
(Fig. 7B). These peptides are targeted again to early endosomes
through the TAP protein before being loaded onto MHC class I
molecules for presentation at the cell surface (Fig. 7B). The authors































































































Fig. 7. Effects of Nod2 on MHC class II antigen presentation and cross-presentation by dendritic cells. (A) Nod2-dependent autophagy can mediate MHC class II antigen
presentation. (B) Upregulation of the cross-presentation and costimulatory molecules by Nod2 signalling.
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wild-typemiceupregulatedDCsexpressionofmolecules involved in
cross-presentation such as Tap-1, calnexin,. . . Furthermore, the
expression of surface costimulatory molecules (CD40, CD86) was
also increased. Accordingly, they postulated that Nod signalling
enhanced the cross-priming of Ag-speciﬁc CD8+ T cells by CD8a+
DCs, at least in part, by upregulating Ag cross-presentation pathway
and costimulation via surface molecules (Fig. 7B). However, while
the authors checked that Nod1 ligand failed to enhance the cross-
priming in Nod1-deﬁcient mice, they did not perform the same
experiment with Nod2/ mice. Unfortunately, they did not
investigate neither the mechanism by which Nod stimulation led
to increased expression of cross-presentation or costimulatory
molecules, the involvement of RIP2, NF-kB and MAPKs nor the
behaviour of CD mutants. Nevertheless, these preliminary results
might open onto the development of novel preventive and
therapeutic applications for viral infections as well as cancer.
Finally, another recent study challenged the current dogma that
Nod2 regulates adaptative immunity through MDP sensing in DCs
by showing a T cell-intrinsic role of Nod2 independent on MDP
recognition [83]. Authors demonstrated that Nod2/ CD4+ T cells
had poor helper T cell differentiation, which was associated with
impairedproductionof IL-2. Preliminary results suggesteda scaffold
role for Nod2 in the pathway leading to c-Rel-mediated IL-2
transcription in response to CD28 costimulation. These ﬁndings are
conﬂicting with previous studies showing that Nod2 is not required
in generating effective Ag-speciﬁc responses after immunization
withother agonists thanMDP [68,78]orwithdatademonstratingno
T cell-intrinsic role for Nod2 [84]. This intringing study will likely
generate further research on Nod2 behaviour in T cells.
6. Nod2 and crohn disease
At least 58 disease-associatedmutations in nod2 gene (CARD15)
have been reported [85]. Approximately 80% of these are
associated with Crohn’s disease (CD), while the remaining 20%
have been linked with Blau syndrome (BS) and early onset
sarcoidosis (EOS).
Most patients with BS/EOS have mutations affecting the Nod2
NBD domain which lead to increased basal and MDP-induced NF-
kB activity [86]. BS/EOS is usually considered as an autoinﬂam-
matory disorder characterized by the usual triad of granulomatous
arthritis, uveitis and dermatitis which develop very early (before 4
years) [85].
CD is a multifactorial inﬂammatory bowel disease (IBD). Unlike
BS/EOSwhich typically have diffuse,multisystemic granulomatous
inﬂammation, CD is characterized by transmural granulomatous
inﬂammation of the gastrointestinal tract. Three major Nod2
polymorphisms are associated to CD: G908R, R702W and a
frameshift insertion mutation at L1007 (L1007fsinsC) [8,9].
Patients homozygous for these mutations have a 20- to 40-fold
increased risk for disease development.
Since these mutations are localized within or near the LRR
domain of Nod2, they prevent CD variants to be efﬁciently
activated by MDP and consequently lead to a loss-of-function
phenotype [14]. PBMCs isolated from CD patients carrying the
L1007fsinsC mutation express reduced levels of pro-inﬂammatory
cytokines such as TNF-a, IL-6 and IL-8 in response to MDP [87,88].
However, these observations are inconsistent with the increase of
NF-kB-dependent inﬂammation observed in clinical samples from
CD patients. Two major hypotheses establish a link between these
‘‘loss-of-function’’ CD mutants and the development of CD.
The ﬁrst hypothesis suggests that the impaired function of
Nod2 in intestinal epithelial and phagocytic cells results in
deﬁciencies in epithelial-barrier function which subsequently
lead to increased bacterial invasion and inﬂammation at intestinal
sites (Fig. 8). Several Nod2-regulated phenomenons can contribute
to the impairment of epithelial-barrier function. On one hand,



































































Fig. 8. Nod2-dependent alterations that affect the intestinal epithelium-barrier function in Crohn’s disease. (A) Normal intestinal epithelium. Paneth cells respond to
pathogens and commensal bacteria by secreting antimicrobial peptides. Epithelial cells, local macrophages and dendritic cells contribute to the bacterial clearance by
mounting an efﬁcient autophagy response and/or bactericidal ROS production. These innate protection mechanisms associated with an efﬁcient CD4+ T immune response
cooperate in the control of bacterial invasion. (B) Intestinal epitheliumexpressing Nod2 variant. Antimicrobial peptides secretion, ROS generation and autophagy do no longer
work. These alterations in innate response in combination with an inadequate CD4+ T immune response promote the bacterial persistence and the generation of secondary
inﬂammatory changes characteristic of CD.
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a-defensins can be downregulated in Paneth cells expressing CD
mutant, which can lead to overgrowth of the intestinal microﬂora
and increased susceptibility to enteric pathogens. This hypothesis
is consistent with two observations: ﬁrst, the reduced expression
of a-defensins at ileal mucosa of CD patients with mutant Nod2
[89] and secondly, the correlation between the increased
susceptibility of Nod2-deﬁcient mice to L. monocytogenes oral
infection and diminished expression of Paneth cell-derived
antimicrobial peptides [68]. On the other hand, the Nod2-
dependent bacteria clearance mechanisms such as autophagy
and bactericidal ROS production can be compromised in intestinal
epithelial and dendritic cells expressing a CD-associated Nod2
mutant [57,58,63]. Interestingly, a ‘‘loss-of-function’’ mutation
(T300A) in ATG16L1, a key regulator of autophagy, was also
associated with a higher susceptibility for CD [90]. The ﬁndings
demonstrating that two of the strongest genetic risk factors in CD
(Nod2 and ATG16L1) are linked in the autophagy pathway
underline the important role of autophagy in intestinal homeosta-
sis. The inability of DCs expressing one or both variants (Nod2
L1007fsinsC or ATG16L1 T300A) to trafﬁc bacteria and present
antigens correctly could lead to inadequate generation of CD4+ T
immune responses, facilitating bacterial persistence and the
generation of secondary inﬂammatory changes characteristic of
CD.
The second hypothesis claims that Nod2 functions as a negative
regulator of TLR2-mediated signalling and loss-of-function Nod2
mutations result in dysregulated TLR2-mediated Th1 inﬂamma-
tion in intestinal macrophages and/or DCs [67].
Finally, a third hypothesis coming from a study performed with
knockin mice expressing the Nod2 frameshift mutant
(L1007fsinsC) suggests this common mutation acts as a gain-of-
function mutation [91]. In this study, macrophages from these
knockin mice exhibit increased NF-kB activation and IL-1b
secretion in response to MDP. However, these results are
conﬂicting with those showing that monocytes from CD patients
homozygous for this frameshiftmutation exhibit a loss-of-function
phenotype [14,88].
7. Conclusions and perspectives
For almost 10 years, Nod2 has been known as an innate
cytosolic receptor able to trigger a RIP-2- and NF-kB-dependent
pro-inﬂammatory and antibacterial response after sensing PGN
from Gram-positive and -negative bacteria. Mutations in the gene
encoding Nod2 in humans have been associated with Crohn’s
disease (CD). Mechanisms by which Nod2 variants can lead to CD
development are still under investigation. The most admitted
hypothesis suggests that the impaired function of Nod2 variants in
intestinal epithelial and phagocytic cells results in deﬁciencies of
epithelial-barrier function which subsequently lead to increased
bacterial invasion and inﬂammation at intestinal sites.
Recent data have shown that Nod2 wild-type, unlike Nod2
variants, can induce autophagy in response to bacterial infection,
thereby allowing efﬁcient bacterial trafﬁcking and MHC class II
antigen presentation. These data reinforce the model of impaired
epithelial-barrier since DCs expressing one variant could lead to
inadequate generation of CD4+ T immune responses, facilitating
bacterial persistence and the generation of secondary inﬂamma-
tory changes characteristic of CD. Further investigation will be
required to elucidate the molecular mechanism involved in Nod2-
mediated autophagy. These new results demonstrating a role of
Nod2 in adaptative immune response have also allowed to better
understand the MDP adjuvanticity known for more than 30 years.
Very recent results have expanded the function of Nod2 beyond
detection of peptidoglycan. Indeed, Nod2 has been shown to confer
responsiveness to viral ssRNA in terms of IRF3 activation and IFNb
production and, by this way, to contribute to antiviral response.
Nod2-mediated IRF3 activation probably proceeds via a mecha-
nism similar to RLRs (RIG-I and MDA-5) involving the mitochon-
drial adaptor protein MAVS. Like for MDP, further studies will be
required to determine whether themechanism of ssRNA sensing is
direct or indirect, involving ‘‘bridging proteins’’.
Interestingly, Nod2 has been also shown to be exquisitely tuned
to detect mycobacterial infections and mount a protective
immunity against these pathogens. As CD is epidemiologically
associated with mycobacterial infections [92], further studies are
needed to determine whether mycobacteria can exploit variability
in Nod2-mediated resistance to initiate or contribute to chronic
inﬂammatory bowel disease.
Another recent study has shown that Nod2 signalling can also
enhance the cross-priming of Ag-speciﬁc CD8+ T cells by CD8a+
DCs, at least in part, by upregulating Ag cross-presentation
pathway and costimulation via surface molecules. The mechanism
by which Nod2 stimulation leads to increased expression of cross-
presentation or costimulatory molecules, the involvement of RIP2,
NF-kB and MAPKs and the behaviour of CD mutants need to be
further explored. Nevertheless, these preliminary results might
open onto the development of novel preventive and therapeutic
applications for viral infections as well as cancer.
Finally, a T cell-intrinsic role of Nod2 independent on MDP
recognition has been suggested. Nod2 would be involved in c-Rel-
mediated IL-2 transcription in response to CD28 costimulation.
While these data have to be further investigated, they elicit the
question concerning the role of Nod2 in other cell types than
monocytes/macrophages, dendritic and epithelial cells. Indeed,
Nod2 has been shown to be expressed in neutrophils [93],
preadipocytes [94], osteoblasts [95], renal tubular epithelial cells
[96],. . .
In addition, Nod2 L1007fsinsC has been also associated with a
growing number of malignant diseases, including early onset
breast cancer [97], non-Hodgkin’s lymphoma [98] and lung cancer
[99]. The molecular mechanisms underlying these associations are
still unclear.
Altogether, these new exciting discoveries raisemany questions
concerning the various potential roles of Nod2 and highlight its
therapeutic potential.
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